This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Illumina (ILMN) Might Surprise This Earnings Season
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
IBM Corp (IBM) Beats on Q4 Earnings; FY17 View Positive
by Zacks Equity Research
International Business Machines Corp (IBM) reported fourth-quarter 2016 non-GAAP earnings of $5.01 per share, which increased 3.5% from the year-ago quarter.
Illumina (ILMN) Q4 Earnings: A Beat in Store for the Stock?
by Zacks Equity Research
We expect Illumina Inc (ILMN) to beat expectations when it reports fourth-quarter 2016 results after the closing bell on Jan 31.
IBM Watson Commerce Adopted by Ernes to Boost Profitability
by Zacks Equity Research
International Business Machines (IBM) has announced that its cloud-based pricing optimization solution - Watson Commerce - has been selected by the Ermes Group.
Illumina and Bio-Rad Unveil Single-Cell Sequencing Solution
by Zacks Equity Research
Illumina, Inc. (ILMN) recently teamed up with Bio-Rad Laboratories (BIO) to launch the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference.
Winning Stock Picking Ideas from Last Week's Jobs Report
by Kevin Matras
Kevin Matras goes over how to find winning stock-picking ideas in the government's 'boring' economic reports. Highlighted stocks include IHS, CST, JACK and ILMN.
IBM Watson Partners with Illumina to Advance Cancer Research
by Zacks Equity Research
International Business Machines (IBM) owned IBM Watson Health Illumina (ILMN) have inked a partnership to achieve better interpretation of genome data.
Illumina (ILMN) Launches NovaSeq Series for $100 Genome
by Zacks Equity Research
Illumina, Inc. (ILMN) recently unveiled the NovaSeq Series, a scalable sequencing solution expected to enable a $100 genome.
Top 3 MedTech Stocks Poised to Gain this Earnings Season
by Zacks Equity Research
A bipartisan group of ten senators signed on a bill to repeal the 2.3% federal excise tax on medical device makers.
Illumina Fettered With Losses: Can It Bounce Back in 2017?
by Zacks Equity Research
During majority of the past one year, Illumina (ILMN) lagged the Zacks classified broader Medical - Biomedical and Genetics industry.